#Global Interventional Cardiology and Peripheral Vascular Devices Market

[gqresearch24]

Absorbable Heart Stent Market Dynamics: Technological Advancements and Consumer Preferences | GQ Research

The Absorbable Heart Stent market is set to witness remarkable growth, as indicated by recent market analysis conducted by GQ Research. In 2023, the global Absorbable Heart Stent market showcased a significant presence, boasting a valuation of US$ 2.78 billion. This underscores the substantial demand for Absorbable Heart Stent technology and its widespread adoption across various industries.

Get Sample of this Report at https://gqresearch.com/request-sample/global-absorbable-heart-stent-market/

Projected Growth: Projections suggest that the Absorbable Heart Stent market will continue its upward trajectory, with a projected value of US$ 4.6 Billion by 2030. This growth is expected to be driven by technological advancements, increasing consumer demand, and expanding application areas.

Compound Annual Growth Rate (CAGR): The forecast period anticipates a Compound Annual Growth Rate (CAGR) of 7%., reflecting a steady and robust growth rate for the Absorbable Heart Stent market over the coming years.

Technology Adoption:

The absorbable heart stent market has witnessed a gradual but steady adoption rate since its inception. Initially, there were reservations regarding the efficacy and safety of absorbable stents compared to traditional metal stents. However, as clinical trials demonstrated comparable outcomes and advantages such as reduced risk of long-term complications, adoption rates have increased. Healthcare providers are increasingly embracing absorbable stents due to their potential to mitigate issues associated with permanent implants, such as late thrombosis and interference with future interventions.

Application Diversity:

The diversity in applications of absorbable heart stents is expanding, driven by advancements in materials science and medical technology. Initially developed for coronary artery disease, absorbable stents are now being explored for peripheral vascular interventions and structural heart procedures. Additionally, ongoing research is investigating their potential in pediatric cardiology and complex lesions. This diversification of applications underscores the versatility and adaptability of absorbable stent technology, opening up new avenues for patient care.

Consumer Preferences:

Consumer preferences in the absorbable heart stent market are evolving in tandem with increased awareness and education. Patients are becoming more proactive in their treatment decisions, seeking alternatives that offer improved safety profiles and reduced long-term risks. Consequently, there is a growing preference for absorbable stents among patients and healthcare professionals alike, especially in younger populations and those with concerns about the long-term effects of permanent implants. This shift in preferences is driving manufacturers to prioritize innovation and address consumer demands for safer and more effective treatment options.

Technological Advancements:

Technological advancements play a pivotal role in shaping the absorbable heart stent market landscape. Innovations in material science have led to the development of bioresorbable polymers with enhanced mechanical properties and biocompatibility. Furthermore, advances in imaging modalities and catheter-based delivery systems have improved procedural precision and patient outcomes. The integration of drug-eluting capabilities and bioactive coatings has also contributed to the refinement of absorbable stent technology, offering targeted therapy and reducing the risk of restenosis. Continuous research and development efforts are expected to drive further technological advancements, ushering in the next generation of absorbable heart stents.

Market Competition:

The absorbable heart stent market is characterized by intense competition among key players and emerging entrants. Established medical device companies are vying for market share through product differentiation, strategic partnerships, and acquisitions. Simultaneously, startups and research institutions are driving innovation with novel designs and manufacturing techniques. Regulatory approvals and clinical evidence play a crucial role in determining market competitiveness, with companies investing heavily in clinical trials and post-market surveillance to demonstrate the safety and efficacy of their products

Environmental Considerations:

Environmental considerations are increasingly influencing the absorbable heart stent market, reflecting broader trends towards sustainability and environmental responsibility in healthcare. The use of bioresorbable materials in stent manufacturing aligns with efforts to reduce the environmental impact of medical devices by minimizing the need for permanent implants and associated waste. Additionally, biodegradable polymers offer the potential for eco-friendly disposal post-procedure, reducing the burden on healthcare facilities and the environment.

Regional Dynamics: Different regions may exhibit varying growth rates and adoption patterns influenced by factors such as consumer preferences, technological infrastructure and regulatory frameworks.

Key players in the industry include:

Abbott Laboratories

Biotronik

Boston Scientific Corporation

Medtronic plc

Biotronik SE & Co. KG

Terumo Corporation

Meril Life Sciences Pvt. Ltd

Elixir Medical Corporation

The research report provides a comprehensive analysis of the Absorbable Heart Stent market, offering insights into current trends, market dynamics and future prospects. It explores key factors driving growth, challenges faced by the industry, and potential opportunities for market players.

For more information and to access a complimentary sample report, visit Link to Sample Report: https://gqresearch.com/request-sample/global-absorbable-heart-stent-market/

About GQ Research:

GQ Research is a company that is creating cutting edge, futuristic and informative reports in many different areas. Some of the most common areas where we generate reports are industry reports, country reports, company reports and everything in between.

Contact:

Jessica Joyal

+1 (614) 602 2897 | +919284395731

Website - https://gqresearch.com/

[delvenservices]

Vascular Closure Devices Market Research Analysis & Forecast: 2028

Vascular Closure Devices Market by Type (Passive Approximators, Active Approximators, External Hemostatic Devices), Access (Femoral, Radial), Procedure (Interventional Cardiology, Interventional Radiology/Vascular Surgery), and Region (North America, Europe, Asia-Pacific, Middle East and Africa and South America)

The Vascular Closure Devices market size is projected to reach a CAGR of 7.2% from 2021 to 2028.

After the angioplasty the puncher so caused in the artery is sealed by using a piece of either collagen, metal strip or a suture. It is a mechanical stitch which gets dissolve in about 60-90 days. The collagen used is made up of sponge.

Higher incidence of cardio vascular disease along with the surge in obese population are some of the factors that have supported long-term expansion for Vascular Closure Devices Market.

COVID-19 had a negative effect on the market, due to the lockdown conditions all across the globe the patients were not able to visit the hospitals and thus the market was negatively affected.

Get the Free Sample Copy of the Research Report: https://www.delvens.com/get-free-sample/vascular-closure-devices-market-trends-forecast-till-2028

Regional Analysis

North America is the most rapidly growing market and offers a huge opportunity as because the prevalence of cardiovascular disease in people is on a rise

Make an Inquiry Before Buying: https://www.delvens.com/Inquire-before-buying/vascular-closure-devices-market-trends-forecast-till-2028

Key Players

Terumo Corporation

Abbott

Cardinal Health

Cardiva Medical, Inc.

Medtronic Plc.

Morris Innovative, Inc.

Teleflex Incorporated

Merit Medical Systems, Inc.

Vasorum Ltd.

TZ Medical, Inc.

Vivasure Medical Ltd.

Tricol Biomedical

Scion Biomedical

Advanced Vascular Dynamics

Recent Developments

In 2021, PerQseal Blue a product of Vivasure Medical Ltd is under development by the company.

In June 2021, In 2021, Abbott took over Walk Vascular, LLC in order to expand its portfolio of peripheral vascular devices.

Reasons to Acquire

Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors

Gain authentic and granular data access for Vascular Closure Devices s Market so as to understand the trends and the factors involved behind changing market situations

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Direct Order of the Report: https://www.delvens.com/checkout/vascular-closure-devices-market-trends-forecast-till-2028

Report Scope

Vascular Closure Devices Market is segmented into Type, Access, Procedure and region.

On the basis of Type

Passive Approximators

Collagen Plugs

Sealant or Gel-based Devices

Compression Assist Devices

Active Approximators

Suture-based Devices

Clip-based Devices

External Hemostatic Devices                                                

On the basis of Access

Femoral Access

Radial Access

On the basis of Procedure

Interventional Cardiology

Interventional Radiology/Vascular Surgery

On the basis of Region

Asia Pacific

North America

Europe

South America

Middle East & Africa

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

SALES@DELVENS.COM

[nitasonwane]

Interventional Cardiology Devices Market Size, Share and Demand 2029

The interventional cardiology devices market refers to the sector of the medical device industry that focuses on devices used in the field of interventional cardiology. Interventional cardiology is a specialized branch of cardiology that involves diagnosing and treating cardiovascular diseases using minimally invasive techniques.

Interventional cardiology devices are designed to perform various procedures inside the blood vessels or heart, with the goal of diagnosing and treating conditions such as coronary artery disease, heart valve disorders, congenital heart defects, and peripheral vascular diseases. These devices are typically used in cardiac catheterization procedures, where a thin, flexible tube called a catheter is inserted into a blood vessel and guided to the heart or other relevant areas.

Some common interventional cardiology devices include:

Coronary Stents: These are small mesh-like devices used to keep narrowed or blocked coronary arteries open. They are often made of metal or a combination of metal and a drug-coated polymer

Catheters: These are thin tubes used for various purposes, such as delivering medications, removing blood clots, or performing angioplasty procedures to open blocked arteries.

Balloon Catheters: These catheters have an inflatable balloon at their tip, which can be inflated to open narrowed or blocked blood vessels. They are commonly used in angioplasty procedures.

Intravascular Ultrasound (IVUS) Systems: These devices use ultrasound technology to generate real-time images of blood vessels from inside the body. They provide detailed information about the vessel's structure and aid in guiding interventions

Embolic Protection Devices: These devices are used to capture and remove debris or blood clots that may dislodge during interventional procedures, preventing them from causing further blockages downstream.

Reduction in Number of Elective Surgeries Impeded Market Growth

The COVID-19 pandemic negatively affected the market in 2020 due to elective surgical procedures across the globe, significantly affecting the global market. According to PLOS, in September 2022, in Michigan, the total PCI procedural volume from March to December 2020 declined by 15.2% compared to 2019. In 2021, all elective and interventional surgeries were conducted in several countries across the globe. Preference for interventional procedures due to non-invasive and infection control among patients is set to propel the market growth.

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them in addressing various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

[meditech-insights]

Interventional Cardiology Devices Market valued at US$ 6.7 billion in 2021, is expected to grow at a CAGR of 2 to 3% by 2026

Interventional cardiology is a branch of cardiology that utilizes nonsurgical, catheter-based treatments for structural heart diseases. It makes use of devices such as catheters & sheaths, guidewires, balloons, stents, vascular closure devices, atherectomy devices, intravascular ultrasound (IVUS), and other devices to repair narrowed arteries, damaged or weakened blood vessels, heart valve disorders, and congenital heart diseases.

The Global Interventional Cardiology Devices Market valued at US$ 6.7 billion in 2021 is set to witness a growth rate of ~2 to 3% in the next 5 years. The rising geriatric population & corresponding rise in the prevalence of coronary artery diseases, rising occurrence of diabetes & concomitant increased risk of coronary heart disease, technical developments in interventional cardiology devices, and favorable reimbursements for interventional cardiology procedures are some of the key factors driving the global interventional cardiology devices market.

APAC to Witness Highest Growth in the Next Five Years

An increasing occurrence of cardiovascular diseases & hypertension, a higher degree of unmet clinical needs, and rising affluence are creating ample opportunities for the interventional cardiology devices market in the APAC region. The development of the interventional cardiology devices market in the APAC is likely to be driven by China and India. Considering the lucrative prospects of the interventional cardiology devices market in the APAC region, prominent companies have expanded their footprint in the region.

For instance,

In March 2022, Boston Scientific expanded its footprint in India with its second R&D Center. The new R&D Center addresses the needs of the patients in India, APAC, and around the world. It also provides expertise to all of the company’s diverse therapy areas, namely interventional cardiology, peripheral interventions, cardiac rhythm management, endoscopy, neuromodulation, urology, and pelvic health

Abbott also intends to expand coverage and resources in training programs related to cardiovascular treatment in China. Abbott owns two training centers in China. The Abbott Medical Advanced Technology Center in Beijing provides doctors with first-class cardiological learning experiences and practice opportunities. The Crossroads-Abbott Academic Center in Shanghai provides interventional treatment training for physicians from different regions in China, making medical treatment and standardized treatment and care more accessible to patients in remote areas

“China is one of the most prominent markets for cardiovascular diseases. The demand from patients to be treated as well as doctors to get trained is humongous. This is why interventional cardiology device manufacturers are investing in China."- Director, Leading Stent Manufacturer, United States

Explore Premium Report on Interventional Cardiology Devices Market @ https://meditechinsights.com/interventional-cardiology-devices-market/

Technological Advancements Drive the Market 

The interventional cardiology devices market is a technology-driven market and is noticeable by product enhancements/innovations.

For instance,

In May, 2022, Medtronic received U.S. FDA approval for the Onyx Frontier™ drug-eluting stent (DES). The Onyx Frontier DES is used for the treatment of patients with coronary artery disease (CAD). It offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent

In April 2022, Translumina launched VIVO ISAR, its latest generation dual drug polymer-free coated stent (DDCS), in various international markets including Europe

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold

The interventional cardiology devices market is characterised by the presence of both established and new players. Players operating in the market adopt both organic and inorganic growth strategies such as acquisitions, and new product launches to gain market share.

For instance,

In April 2022, Transit Scientific announced the FDA clearance of its XO Cross® Support Catheter Platform to include coronary use. The platform is indicated to guide and support a guidewire during access of the peripheral or coronary vasculature, allow for wire exchanges, and provide a conduit for delivery of saline solutions or diagnostic contrast agents

In April 2022, Boston Scientific announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures. The acquisition allows Boston Scientific to integrate the Baylis platforms with its existing electrophysiology and structural heart offerings, further strengthening its position in the cardiology market

The interventional cardiology devices market is anticipated to continue to grow in the coming years due to rising cardiovascular cases, growth opportunities in the APAC region, technical developments in interventional cardiology devices, and favorable reimbursement in key markets.

Competitive Landscape Analysis of Interventional Cardiology Devices Market

The interventional cardiology devices market is marked by the presence of players such as Medtronic, Boston Scientific, Abbott, Medinol, Biotronik, SMT, Terumo, Lepu Medical, Microport, among others.

For More Comprehensive Insights, Contact Us @ https://meditechinsights.com/contact-us/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com

[medi-techinsights]

Global Interventional Cardiology Devices Market is projected to witness a decent growth rate of 2 to 3% by 2026

Interventional cardiology is a branch of cardiology that utilizes nonsurgical, catheter-based treatments for structural heart diseases. It utilizes devices such as catheters & sheaths, guidewires, balloons, stents, vascular closure devices, atherectomy devices, intravascular ultrasound (IVUS), and other devices to repair narrowed arteries, damaged or weakened blood vessels, heart valve disorders, and congenital heart diseases.

Rising prevalence of cardiovascular diseases & hypertension, a higher degree of unmet clinical needs, and rising affluence are creating ample opportunities for the interventional cardiology devices market in the APAC region. The growth of the interventional cardiology devices market in the APAC is likely to be driven by China and India.

Technological Innovations Drives the Interventional Cardiology Devices Market Growth

The global interventional cardiology devices market is a technology-driven market and is marked by product innovations. For instance,

In May, 2022, Medtronic received U.S. FDA approval for the Onyx Frontier™ drug-eluting stent (DES). The Onyx Frontier DES is used for the treatment of patients with coronary artery disease (CAD). It offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent.

In April 2022, Translumina launched VIVO ISAR, its latest generation dual drug polymer-free coated stent (DDCS), in various international markets including Europe.

Growth Strategies Adopted by Market Players to Establish Their Foothold in Interventional Cardiology Devices Market

The global interventional cardiology devices market is marked by the presence of both established and emerging players. Players operating in this market have adopted both organic and inorganic growth strategies such as acquisitions, and new product launches to garner higher market share. For instance,

In April 2022, Transit Scientific announced the FDA clearance of its XO Cross® Support Catheter Platform to include coronary use. The platform is indicated to guide and support a guidewire during access of the peripheral or coronary vasculature, allow for wire exchanges, and provide a conduit for delivery of saline solutions or diagnostic contrast agents.

The interventional cardiology devices market is expected to grow in the upcoming years due to increasing cardiovascular cases, emerging growth opportunities in the APAC region, technological advancements in interventional cardiology devices, and favourable reimbursement in key markets.

Competitive Landscape Analysis: Interventional Cardiology Devices Market

The market is marked by the presence of key market players such as Medtronic, Boston Scientific, Abbott, Medinol, Biotronik, SMT, Terumo, Lepu Medical, Microport, among others.

Get Customized Report on Interventional Cardiology Devices Market @ https://meditechinsights.com/interventional-cardiology-devices-market/

[healthcaremresearch]

Inflation Devices Market Analysis, Business Development, Size, Share, Trends, Future Growth, Forecast to 2030

The global inflation devices market accounted for $517 million in 2018, and is expected to reach $770 million by 2026, registering a CAGR of 5.1% from 2019 to 2026.

Inflation Devices Market is developing primarily due to the escalating use of minimally invasive processes, the existence of robust medical facilities in the most of the developed nations. The 20ml, 30ml, and 60ml inflating devices market is divided into segments. During the forecast period, the segment for 60ml inflation devices is anticipated to increase at the quickest CAGR. Since pulmonary, gastroenterology, and otolaryngology procedures use somewhat larger-sized balloons and require more liquid for inflation, these devices' quick-latch mechanisms (for one-handed deflation) and ease of use have led to their popularity in these procedures.

Healthcare sector will further create new opportunities for inflation device market in the forecasted period of 2021-2028.  An increase in the number of elderly people with chronic conditions like urological diseases and CVDs is anticipated to drive growth in the market for inflation devices worldwide. Additionally, a rise in demand for less invasive treatments is anticipated to fuel the market. According to WHO, cardiovascular diseases are the main global cause of death. Rapid product approvals enable the businesses to strengthen their position in the market. The high cost of cardiac devices and the availability of numerous substitute devices, however, are predicted to place limitations on the market.

Top Key Players:

Becton, Dickinson and Company

Cook Medical

Advanced Lifesciences Pvt. Ltd.

Boston Scientific Corporation

Conmed Corporation

B. Braun Melsungen AG

Cardinal Health

Medtronic PLC

Acclarent, Inc.

Atrion Corporation

By Types:

Analogue Inflation Devices

Digital Inflation Devices

Request a sample copy of the report: @ https://healthcaremarketreports.com/sample-request/inflation-devices-market/68902/?utm_source=Niraj&utm_medium=Free

By Applications:

Gastroenterological Procedures

Urological Procedures

Intervention Cardiology & Radiology

Peripheral Vascular Procedures

By Regions:

North America

Europe

China

Japan

Middle East and Africa

South America

India

South Korea

Southeast Asia

Others

Some Points from Table of Content:

1 Market Overview

2 Manufacturers Profiles

3 Blood Glucose Analysis Systems Sales by Manufacturer

4 Market Analysis by Region

5 Market Segment by Type

6 Market Segment by Application

7 North America by Country, by Type, and by Application

8 Europe by Country, by Type, and by Application

9 Asia-Pacific by Country, by Type, and by Application

10 South America by Country, by Type, and by Application

11 Middle East & Africa by Country, by Type, and by Application

12 Sales Channel, Distributors, Traders and Dealers

13 Research Findings and Conclusion

14 Appendix

Purchase this report:@ https://healthcaremarketreports.com/purchase/inflation-devices-market/68902/?license=single  

FAQs:

What is the driving factor for the growth of the Inflation Devices market?

How will the COVID-19 pandemic impact the demand and consumption of the Inflation Devices market?

What is the major application area of the Inflation Devices market?

Who are the Inflation Devices manufacturers across the globe?

Which geographical location is dominant in the Inflation Devices market?

Which are the top industry players in the Inflation Devices market?

About Us:

he healthcare industry is surely facing disruptions with global economies giving high importance to individual health. In this scenario, we expect our clients to get deep insights to power their innovations in the right direction. We have been keeping a close watch on the changes and modifications happening in the healthcare domain. As per our understanding, these alterations are active and unexampled.

Contact Us:

Healthcare Market Reports

sales@healthcaremarketreports.com    

+1(929)-450-2887

[gurudige9987]

The global interventional cardiology and peripheral vascular devices market size was valued at $17,960.8 million in 2020, and is projected to reach $41,900.3 million by 2030, growing at a CAGR of 8.8% from 2021 to 2030

[metiresearchinfo]

TOP 10 COMPANIES IN INTERVENTIONAL ONCOLOGY MARKET

Interventional oncology is an emerging and rapidly growing offshoot of interventional radiology, which emphasizes on the use of minimally-invasive procedures for the diagnosis, treatment, and palliative care for cancer patients. It uses image-guided technologies such as CT, fluoroscopy or ultrasound to target tumor lesions by making small puncture in the skin. Interventional oncology is generally meant for patients who are not able to respond positively towards the chemotherapy or radiation, or ones are unable to undergo surgery.

The global interventional oncology market is expected to grow at a CAGR of 7.7% from 2019 to 2025 to reach $1,506.3 million by 2025.

Here are the Top 10 Companies in Interventional Oncology :

Boston Scientific Corporation (U.S.)

Founded in 1979 and headquartered at Massachusetts, the U.S.; Boston Scientific Corporation (U.S.) is a developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties. The company operates through three business segments namely Cardiovascular, Rhythm and Neuro, and MedSurg. The company provides interventional oncology products under the cardiovascular business segment. In cardiovascular business segment, the company provides technologies for diagnosing and treating coronary artery diseases, and other cardiovascular disorders including structural heart conditions under two sub-segments namely Interventional Cardiology and Peripheral Interventions. The Peripheral Interventions division offers devices used in peripheral angioplasty and peripheral vascular diseases along with interventional oncology products like peripheral embolization devices, microcatheters, and drainage catheters.

With its subsidiaries and strong network of distribution, the company has its presence in various regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The major subsidiaries of Boston Scientific Corporation are American Medical Systems Inc. (U.S.), Cameron Health, Inc. (U.S.), Boston Scientific Japan K.K. (Japan), and more.

Cook Medical LLC

Founded in 1963 and headquartered at Indiana, the U.S.; Cook Medical LLC is a manufacturer of minimally invasive medical devices. The company provides medical devices for 41 medical specialities including diagnostic radiology, endourology, gynecology, interventional radiology, obstetrics, and more. The company has two business divisions namely vascular and MedSurg. The company provides interventional oncology products under the vascular division. With its subsidiaries and strong network of distributors, the company has its presence across 135 countries.

The major subsidiaries of the company include Cook MyoSite Incorporated (U.S.) and Cook Urology (U.S.).

Merit Medical Systems, Inc.

Founded in 1987 and headquartered at Utah, the U.S.; Merit Medical Systems, Inc. is a manufacturer and marketer of disposable medical devices used across various therapeutic areas like cardiology, radiology, oncology, critical care, and endoscopy for the diagnosis, treatment therapy, and surgical intervention procedures. The company offer products for wide range of clinical area including interventional cardiology; electrophysiology; cardiac rhythm management; interventional oncology; pain management; and more. The company operates through two financial business segments namely cardiovascular and endoscopy. The company provides interventional oncology related products under the cardiovascular business segment.

With its subsidiaries and network of distribution, the company has its presence across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The major subsidiaries of the company include Merit Medical GmbH (Germany), BioSphere Medical, Inc. (U.S.), Merit Medical Austria GmbH (Austria).

C.R. Bard, Inc.

Founded in 1907 and headquartered at New Jersey, the U.S.; C. R. Bard, Inc. is a developer, manufacturer, and marketer of Vascular, Urology, Oncology, and Surgical products. The company focuses on the development of single-patient-use medical products for hospital procedures and is dedicated to pursuing technological innovations to offer superior clinical benefits while helping to reduce overall health care costs. The company markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. The company provides interventional oncology products under the segment BD Interventional.

With its subsidiaries and strong network of distribution, the company has its presence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. In December 2017, the company was acquired by Becton, Dickinson and Company (U.S.). This acquisition expanded the product offering of Becton, Dickinson, and Company across the care continuum and offered growth opportunities for both the companies in non-U.S. markets.

Profound Medical Corp.

Incorporated in 2008 and headquartered at Mississauga, Canada; Profound Medical Corp. is a developer and manufacturer of therapeutic platform that provides the precision of real-time MR imaging combined with the safety and accuracy of directional (inside-out) and focused (outside-in) ultrasound technology for incision-free ablation of diseased tissue. The company serves wide range of customers, which includes academic/university/clinical leadership hospitals as well as private clinics with access to MRI scanners. The company relies on its strategic partners, including Koninklijke Philips N.V. (the Netherlands) and Siemens AG (Germany), for lead generation and distribution of the capital units.

With its subsidiaries and strong network of distribution, the company has its presence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The major subsidiaries of the company include Profound Medical Inc. (Canada), Profound Medical Oy (Finland), Profound Medical GmbH (Germany), and Profound Medical (U.S.) Inc.

A report into the projected growth of the current Interventional Oncology Market by Meticulous Research® has produced some incredible forecasts for the industry. By 2025, it’s expected to have grown at a CAGR of 7.7%, reaching over $ 1.5 billion.

AngioDynamics, Inc.

Founded in 1988 and headquartered at New York, the U.S.; AngioDynamics, Inc. is engaged in designing, manufacturing, and selling of medical, surgical and diagnostic devices. These devices are used by healthcare professionals for the treatment of peripheral vascular disease, vascular access, oncology, and surgical settings. Moreover, these products are applicable for minimally invasive and image guided procedures. The company operates through three business segments namely Peripheral Vascular (“PV”), Oncology/Surgery (“OS”) and Vascular Access (“VA”). The company offers interventional oncology products under Oncology/Surgery business segment.

With its subsidiaries and strong network of distribution, the company has its presence across North America and other regions. The subsidiaries of the company are Navilyst Medical (U.S.), Vortex Medical, Inc. (U.S.), and AngioDynamics UK Ltd. (U.K.).

BTG plc

Incorporated in 1991 and headquartered at London, the U.K.; BTG plc is a healthcare company focusing on interventional medicine. The company provides products for the treatment of cancer, vascular conditions and severe emphysema. The company operates its business through three segments namely Interventional Medicine, Pharmaceuticals, and Licensing. The company offers interventional oncology products specifically for embolization, ablation, and cryoablation therapies under interventional medicine segment.

With its subsidiaries and strong network of distribution, the company has its presence across North America, Europe, Asia, and Australia. Biocompatibles International plc (U.K.), Protherics Inc. (U.S.), and Galil Medical Ltd (Israel) are few subsidiaries of the company.

Terumo Corporation

Founded in 1921 and headquartered at Tokyo, Japan; Terumo Corporation is engaged in manufacturing and selling of medical products and equipment, including pharmaceuticals, nutritional food supplement, blood bags, disposable medical devices, cardiovascular systems, vascular grafts, peritoneal dialysis products, blood glucose monitoring system, medical electronic, and digital thermometers. The company offers these products through three business segments namely Cardiac & Vascular Company, General Hospital Company, and Blood Management Company. The company provides interventional oncology products under Terumo Interventional Systems Division of Cardiac & Vascular Company business segment.

With its subsidiaries and strong network of distribution, the company has its presence across North America, Europe, Asia Pacific, and Rest of World. Terumo Medical Corporation (U.S.) and Terumo BCT, Inc. (U.S.) are few subsidiaries of the company.

Medtronic plc

Founded in 1949 and headquartered at Dublin, Ireland; Medtronic plc is engaged in developing and manufacturing medical technology, solutions, and services to reduce the pain with restoring health, and extending life for millions of people around the world. The company provides various medical products through four reportable segments namely Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The company offers interventional oncology products under minimally invasive therapies group business segment.

With its subsidiaries and strong network of distribution, the company has its presence across North America, Europe, Asia Pacific, and Rest of World. Covidien Ltd. (Ireland), Medtronic Limited (U.K.), Medtronic CoreValve LLC (U.S.) are few subsidiaries of the company.

HealthTronics, Inc.

Founded in 1989 and headquartered at Texas, the U.S.; HealthTronics, Inc. is engaged in providing integrated minimally invasive mobile technology-based products and services. The company offers lithotripsy, lasers, cryotherapy equipment, surgical nerve monitoring and microwave ablation as well as repair and maintenance services.

The company serves to hospitals and physicians. The company has healthcare facilities throughout the U.S. The company provides various products through its subsidiaries namely Endocare, Inc. (U.S.), Mobile Solutions, LLC (U.S.), and others.

Popular Mention: EDAP TMS S.A., Neuwave Medical, Inc., Sirtex Medical Limited, Trod Medical, Teleflex Incorporated, and IMBiotechnologies Ltd.

Authoritative Research on the Interventional Oncology Market – Global Opportunity Analysis and Industry Forecast (2019-2025)

Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:

Recent financial performance

Key products

Significant company strategies

Partnerships and acquisitions

The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.

[hemantallied]

Angioplasty stent systems are estimated to generate the highest revenue among all segments throughout the forecast period, owing to technological advancements and development of bioabsorbable stents. North America held the leading position in the global market in 2015, and is expected to maintain its lead in the future. This is attributed to the increase in incidence of heart failures, changes in lifestyle, and high adoption of interventional cardiology and peripheral vascular devices in the region.